ARTA
PLX icon

A.R.T. Advisors’s Protalix BioTherapeutics PLX Stock Holding History

A.R.T. Advisors’s Portfolio PLX Stock Details PLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-38,196
Closed -$319K – 1592
2017
Q2 		$319K Buy
38,196
+16,756
+78% +$157K 0.02% 987
2017
Q1 		$291K Buy
+21,440
New +$193K 0.01% 1014
2016
Q2 		– Sell
-2,221
Closed -$18K – 1573
2016
Q1 		$18K Sell
2,221
-5,790
-72% -$49.6K ﹤0.01% 1320
2015
Q4 		$81K Buy
8,011
+5,317
+197% +$54.1K ﹤0.01% 1349
2015
Q3 		$31K Hold
2,694
– – ﹤0.01% 1305
2015
Q2 		$52K Sell
2,694
-240
-8% -$4.98K ﹤0.01% 1408
2015
Q1 		$52K Sell
2,934
-10
-0.3% -$196 ﹤0.01% 1359
2014
Q4 		$54K Buy
2,944
+1,691
+135% +$36.3K ﹤0.01% 1341
2014
Q3 		$30K Buy
+1,253
New +$36.1K ﹤0.01% 1259
2014
Q2 		– Sell
-1,700
Closed -$77K – 1478
2014
Q1 		$77K Sell
1,700
-432
-20% -$20.2K ﹤0.01% 1253
2013
Q4 		$82K Sell
2,132
-384
-15% -$16.2K ﹤0.01% 1204
2013
Q3 		$113K Sell
2,516
-1,190
-32% -$61.1K 0.01% 1207
2013
Q2 		$181K Buy
+3,706
New +$197K 0.01% 1172

Other funds holding PLX

HCM
Highbridge Capital Management New York $3.09B AUM 31.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

A.R.T. Advisors's PLX Position: Q3 2017 in Review

A.R.T. Advisors sold out of Protalix BioTherapeutics (PLX) in Q3 2017, closing a stake of 38,196 shares — an estimated $319K sold.

A.R.T. Advisors first reported a position in PLX in Q2 2013 and held it in 13 quarters. The position peaked at $319K in Q2 2017. 34 funds tracked by Wall St. Rank hold PLX as of Q3 2017.

  • A.R.T. Advisors reported no remaining Protalix BioTherapeutics position as of Q3 2017 after selling out during the quarter.
  • A.R.T. Advisors sold 38,196 Protalix BioTherapeutics shares in Q3 2017, an estimated $319K.
  • A.R.T. Advisors first reported a position in Protalix BioTherapeutics in Q2 2013 and held it in 13 quarters.
  • A.R.T. Advisors's Protalix BioTherapeutics position peaked at $319K in Q2 2017.
  • 34 funds tracked by Wall St. Rank held Protalix BioTherapeutics as of Q3 2017.

Based on A.R.T. Advisors's 13F filing for Q3 2017, filed 14 Nov 2017.